ArticleJournal of the American Heart Association2026
Automated Classification of Mitral and Tricuspid Regurgitation With Explainability and Real-World Practice Experience.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reinventing the echocardiography workflow: from manual quantification to artificial intelligence-driven comprehensive interpretation.Journal of cardiovascular imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitral regurgitation and tricuspid regurgitation frequently coexist and are evaluated using overlapping echocardiographic views. Although artificial intelligence-based approaches have shown promise, current existing models lack explainability and physiologic constraints, limiting their reliability and adoption in real-world echocardiographic workflows.
methodsWe developed an end-to-end, explainable, flow-aware deep learning pipeline that automatically selects relevant echocardiographic views from routine Digital Imaging and Communications in Medicine files, performs valve morphology assessment via leaflet pose estimation, incorporates systolic phase awareness for Doppler interpretation, and jointly grades mitral regurgitation and tricuspid regurgitation severity from transthoracic echocardiography. The model was trained and internally tested using 5086 outpatient studies from a tertiary center and externally validated in independent cohorts from 2 additional institutions. Model performance was evaluated using area under the receiver operating characteristic curve, sensitivity, specificity, positive predictive value, and negative predictive value, with subgroup analyses across key clinical strata.
resultsIn the internal test set, the model demonstrated excellent discrimination for clinically significant (moderate or greater) mitral regurgitation and tricuspid regurgitation (area under the receiver operating characteristic curve >0.980), with high negative predictive values (>0.970). Performance remained robust across age, sex, and valvular comorbidities, with modest attenuation observed in patients with atrial fibrillation or reduced left ventricular ejection fraction. In the external cohort, areas under the receiver operating characteristic curve were modestly lower, particularly for severe regurgitation; however, sensitivity and negative predictive value remained high.
conclusionsThis explainable, unified artificial intelligence framework enables accurate and efficient screening of mitral regurgitation and tricuspid regurgitation in routine practice. By maintaining strong rule-out capability and robust external performance, the proposed system supports automated triage and prioritization of echocardiographic studies in both specialist and noncardiology settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.